KZR vs. CRGX, VXRT, ACRV, CDTX, ALEC, ACRS, IKT, GLSI, IPHA, and FATE
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include CARGO Therapeutics (CRGX), Vaxart (VXRT), Acrivon Therapeutics (ACRV), Cidara Therapeutics (CDTX), Alector (ALEC), Aclaris Therapeutics (ACRS), Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), Innate Pharma (IPHA), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry.
Kezar Life Sciences vs.
CARGO Therapeutics (NASDAQ:CRGX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership.
CARGO Therapeutics has higher earnings, but lower revenue than Kezar Life Sciences. CARGO Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 1.4% of CARGO Therapeutics shares are owned by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, CARGO Therapeutics had 3 more articles in the media than Kezar Life Sciences. MarketBeat recorded 3 mentions for CARGO Therapeutics and 0 mentions for Kezar Life Sciences. CARGO Therapeutics' average media sentiment score of 0.02 beat Kezar Life Sciences' score of 0.00 indicating that CARGO Therapeutics is being referred to more favorably in the media.
Kezar Life Sciences received 122 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. However, 66.67% of users gave CARGO Therapeutics an outperform vote while only 56.90% of users gave Kezar Life Sciences an outperform vote.
CARGO Therapeutics' return on equity of -38.16% beat Kezar Life Sciences' return on equity.
CARGO Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 297.88%. Kezar Life Sciences has a consensus price target of $39.50, suggesting a potential upside of 552.89%. Given Kezar Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than CARGO Therapeutics.
CARGO Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Summary
CARGO Therapeutics beats Kezar Life Sciences on 9 of the 15 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KZR) was last updated on 2/22/2025 by MarketBeat.com Staff
